This statistic displays the number of substance abuse treatment clients in the United States by substance abuse problem from 2007 to 2020. In 2020, there were 569,522 clients in with drug abuse only in substance abuse treatment facilities.

A survey in 2023 found that more than half of U.S. adults reported someone in their family had been addicted to alcohol at some point in their lifetime. Astoundingly, nearly one in ten adults reported a family member had died from a drug overdose. This statistic shows the percentage of adults who reported someone in their family had ever had select substance abuse problems in the United States as of 2023.

Abstract (en): The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2004 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey and retained through the 2003 survey. Background information includes gender, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. In addition, in 2004 Adult and Adolescent Mental Health modules were added. The "basic sampling weights" are equal to the inverse of the probabilities of selection of sample respondents. To obtain "final NSDUH weights," the basic weights were adjusted to take into account dwelling unit-level and individual-level nonresponse and then further adjusted to ensure consistency with intercensal population projections from the United States Bureau of the Census. In the 2004 NSDUH, a split-sample design for respondents aged 18 or older was implemented. Thus in 2004, two additional person-level analysis weights other than ANALWT_C were created. They are SPDWT_C and DEPWT_C. These weights were created for specific types of person-level analyses. Depending on the section(s) of the 2004 survey from which the variable(s) originated, one of the three sampling weights must be selected and applied. Please refer to the Processor Notes in the codebook for details on determining the appropriate weight to use when analyzing a specific variable or combination of variables. ICPSR data undergo a confidentiality review and are altered when necessary to limit the risk of disclosure. ICPSR also routinely creates ready-to-go data files along with setups in the major statistical software formats as well as standard codebooks to accompany the data. In addition to these procedures, ICPSR performed the following processing steps for this data collection: Performed consistency checks.; Created online analysis version with question text.; Checked for undocumented or out-of-range codes.. Response Rates: The study yielded a weighted screening response rate of 91 percent and a weighted interview response rate for the Computer Assisted Interview (CAI) of 77 percent. The civilian, noninstitutionalized population of the United States aged 12 and older, including residents of noninstitutional group quarters such as college dormitories, group homes, shelters, rooming houses, and civilians dwelling on military installations. A multistage area probability sample for each of the 50 states and the District of Columbia was used since 1999. The 2004 sample design is a continuation of the coordinated five-year sample design th...

In 2023, there were an estimated 32,156 homeless people with chronic substance abuse problems living in emergency shelters in the United States. A further 65,828 homeless people with chronic substance abuse problems were unsheltered in that year.

This series measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, anabolic steroids, and tobacco among members of United States households aged 12 and older. Questions include age at first use, as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, inhalants, cocaine, hallucinogens, heroin, alcohol, tobacco, and nonmedical use of psychotherapeutics. Respondents were also asked about problems resulting from their use of drugs, alcohol, and tobacco, their perceptions of the risks involved, insurance coverage, and personal and family income sources and amounts. Demographic data include sex, race, ethnicity, educational level, job status, income level, household composition, and population density. This study has 1 Data Set.

From June 24 to June 30, 2020, around 40.9 percent of adults aged 18 years or older in the U.S. reported having one or more adverse mental or behavioral health symptoms during the COVID-19 pandemic. This statistic illustrates the percentage of U.S. adults who reported adverse mental health symptoms, increased substance use, and suicidal ideation during COVID-19 pandemic from June 24 to 30, 2020.

Database of the nation''s substance abuse and mental health research data providing public use data files, file documentation, and access to restricted-use data files to support a better understanding of this critical area of public health. The goal is to increase the use of the data to most accurately understand and assess substance abuse and mental health problems and the impact of related treatment systems. The data include the U.S. general and special populations, annual series, and designs that produce nationally representative estimates. Some of the data acquired and archived have never before been publicly distributed. Each collection includes survey instruments (when provided), a bibliography of related literature, and related Web site links. All data may be downloaded free of charge in SPSS, SAS, STATA, and ASCII formats and most studies are available for use with the online data analysis system. This system allows users to conduct analyses ranging from cross-tabulation to regression without downloading data or relying on other software. Another feature, Quick Tables, provides the ability to select variables from drop down menus to produce cross-tabulations and graphs that may be customized and cut and pasted into documents. Documentation files, such as codebooks and questionnaires, can be downloaded and viewed online.

The Residential Substance Abuse Treatment (RSAT) for State Prisoners Formula Grant Program, created by Title III (Subtitle U of the Violent Crime Control and Law Enforcement Act of 1994), was designed by Congress to implement residential substance abuse programs providing individual and group treatment for inmates in residential facilities operated by state and local correctional agencies. Under the Corrections Program Office of the Office of Justice Programs of the United States Department of Justice, state and local correctional agencies received funds to develop or enhance existing programs that: (1) lasted between six and 12 months, (2) provided residential treatment facilities set apart from the general correctional population, (3) were directed at the substance abuse problems of the inmate, (4) were intended to develop the inmate's cognitive, behavioral, social, vocational, and other skills in order to treat related problems as well as the substance abuse, and (5) continued to require urinalysis and/or other proven reliable forms of drug and alcohol testing of individuals assigned to treatment programs during and after release from residential custody. The National Development and Research Institutes, Inc. (NDRI) entered into a cooperative agreement with the National Institute of Justice wherein NDRI would evaluate the extent to which the goals of the RSAT program were being accomplished and the problems that were encountered by the participating states. The methods of this national evaluation were: (1) an initial state survey to ascertain the RSAT programs and program directors in each of the 50 states plus five territories and the District of Columbia and to collect basic information on the aggregate impact of the RSAT-funded programs in each state or territory (Part 1, State Data), (2) a follow-up state survey to collect more detailed information on the aggregate impact of the RSAT-funded programs in each state (Part 1, State Data), and (3) an initial program survey to describe the separate RSAT programs as they came on line and to assess whether a few of the programs might serve as model programs which could undergo subsequent intensive evaluation (Part 2, Program Data). The sampling method used was a census of all the existing RSAT-funded programs and all of the state RSAT officials. Part 1 variables include the amount of RSAT funds received by the state in fiscal years 1996 to 1998, amounts from other sources of funding, and amount spent on salaries, training, drug tests, other supplies, and facilities, as well as number of residents, number of staff, reasons why funding was delayed, RSAT award date, and RSAT end date. Part 2 variables include the number of clients in the program, number of beds available, number of staff by gender, race, age, education, profession, and years of experience, admission inclusion criteria, reporting procedures, treatment type and duration, type of drug testing and number of tests, annual budget, sources of funding, and cost per capita.

The Strategic Prevention Framework State Incentive Grant (SPF SIG) National Cross-Site Evaluation was conducted to evaluate the Center for Substance Abuse Prevention (CSAP)'s SPF SIG initiative, which sought to: (1) prevent the onset and reduce the progression of substance abuse, including childhood and underage drinking; (2) reduce substance abuse-related problems in communities; and (3) build prevention capacity and infrastructure at the state and community levels. This cross-site evaluation included the 21 states and territories CSAP funded in FY2004 (Cohort 1) and an additional 5 States funded in Cohort 2 in FY2005 that were funded for up to 5 years to implement the SPF. The SPF is a five-step prevention planning model that requires states to: (1) conduct a statewide needs assessment, including the establishment of a State Epidemiological and Outcomes Workgroup (SEOW); (2) mobilize and build state and community capacity to address needs; (3) develop a statewide strategic plan for prevention; (4) implement evidence-based prevention, policies, and practices (EBPPP) to meet state and community needs; and (5) monitor and evaluate the implementation of their SPF SIG project. Under contract to the Substance Abuse and Mental Health Services Administration (SAMHSA) with funding provided by the National Institute on Drug Abuse (NIDA), Westat, in collaboration with the Pacific Institute for Research and Evaluation (PIRE) and The MayaTech Corporation, implemented a multilevel, multi-method quasi-experimental design to evaluate SPF SIG's impact. The scope of the evaluation encompassed national, state, and community levels. The design included comparison conditions at both the state and community levels. These data represent Phase I of the restricted use data release and contains extensive data on state-level implementation, community-level implementation, and state-level infrastructure, as well as other reference elements. A subsequent release (Phase II) will include state- and community-level outcomes, as well as data on community-level implementation, community-level implementation fidelity, state-level sustainability, and mediating variables.

In the United States, the percentage of adults who stated they had ever had trouble in their family due to drug abuse rose from 19 percent in 1995 to 32 percent in 2021. This statistic shows the percentage of U.S. adults who reported drug abuse had ever caused trouble in their family from 1995 to 2021.

Despite a growing consensus among scholars that substance abuse treatment is effective in reducing offending, strict eligibility rules have limited the impact of current models of therapeutic jurisprudence on public safety. This research effort was aimed at providing policy makers some guidance on whether expanding this model to more drug-involved offenders is cost-beneficial. Since data needed for providing evidence-based analysis of this issue were not readily available, micro-level data from three nationally representative sources were used to construct a 40,320 case synthetic dataset -- defined using population profiles rather than sampled observation -- that was used to estimate the benefits of going to scale in treating drug involved offenders. The principal investigators combined information from the NATIONAL SURVEY ON DRUG USE AND HEALTH, 2003 (ICPSR 4138) and the ARRESTEE DRUG ABUSE MONITORING (ADAM) PROGRAM IN THE UNITED STATES, 2003 (ICPSR 4020) to estimate the likelihood of drug addiction or dependence problems and develop nationally representative prevalence estimates. They used information in the DRUG ABUSE TREATMENT OUTCOME STUDY (DATOS), 1991-1994 (ICPSR 2258) to compute expected crime reducing benefits of treating various types of drug involved offenders under four different treatment modalities. The project computed expected crime reducing benefits that were conditional on treatment modality as well as arrestee attributes and risk of drug dependence or abuse. Moreover, the principal investigators obtained estimates of crime reducing benefits for all crimes as well as select sub-types. Variables include age, race, gender, offense, history of violence, history of treatment, co-occurring alcohol problem, criminal justice system status, geographic location, arrest history, and a total of 134 prevalence and treatment effect estimates and variances.

In 2023, a survey found that among U.S. adults with personal or family addiction experience, white adults more often reported that they or their family member ever got treatment for their drug addiction or substance use disorder.

This statistic portrays the share of adults in the U.S. with personal or family addiction experience who said they or a family member ever got treatment for drug addiction or substance abuse disorder as of 2023, by race and ethnicity.

description:

This file includes data from the 2002 through 2011 National Survey on Drug Use and Health (NSDUH) survey. The only variables included in the data file are ones that were collected in a comparable manner across one or more of the pair years, i.e., 2002-2003, 2004-2005, 2006-2007, 2008-2009, 2010-2011, or 2012-2013.
The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment. The survey included questions concerning treatment for both substance abuse and mental health-related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Certain questions are asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Also included are questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Demographic information includes gender, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition.
In the income section, which was interviewer-administered, a split-sample study had been embedded within the 2006 and 2007 surveys to compare a shorter version of the income questions with a longer set of questions that had been used in previous surveys. This shorter version was adopted for the 2008 NSDUH and will be used for future NSDUHs.This study has 1 Data Set.

This file includes data from the 2002 through 2011 National Survey on Drug Use and Health (NSDUH) survey. The only variables included in the data file are ones that were collected in a comparable manner across one or more of the pair years, i.e., 2002-2003, 2004-2005, 2006-2007, 2008-2009, 2010-2011, or 2012-2013.
The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment. The survey included questions concerning treatment for both substance abuse and mental health-related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Certain questions are asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Also included are questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Demographic information includes gender, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition.
In the income section, which was interviewer-administered, a split-sample study had been embedded within the 2006 and 2007 surveys to compare a shorter version of the income questions with a longer set of questions that had been used in previous surveys. This shorter version was adopted for the 2008 NSDUH and will be used for future NSDUHs.This study has 1 Data Set.

This pilot study was conducted in an attempt to better understand the jailed population in terms of the number of families at risk and the relationship between parental substance use and incarceration and its impact on the children of the incarcerated. The aim of the study was to describe the jailed population, their needs in relation to substance abuse and parenting issues, to explore children's risk factors resulting from having a parent with substance abuse and/or criminal justice involvement, and ultimately to offer a point of intervention for parents and children at risk. Participants included 229 men and 52 women aged 18 and older, who were in their first 48 hours of incarceration in the Santa Clara County Department of Corrections in August 2003 and who where voluntary participants in the National Institute of Justice's (NIJ) Arrestee Drug Abuse Monitoring (ADAM) Program (ARRESTEE DRUG ABUSE MONITORING (ADAM) PROGRAM IN THE UNITED STATES, 2003 [ICPSR 4020]). Male subjects were chosen through a random selection process, while female participants were taken from a convenience sample. The pilot study used a questionnaire completed as an addendum to the ADAM program main interview. Major types of variables included in this study are type and duration of alcohol/drug use, family history of incarceration, number and ages of children for whom the respondent was the primary caregiver, social consequences for the child due to the incarceration of the respondent, and if the child had any problems with drugs and/or alcohol.

This statistic displays the number of substance abuse treatment facilities in the United States by operation type and client substance abuse problem treated, as of 2020. There were 299 local, county, or community government run substance abuse treatment facilities that treated clients with drug abuse problems only.

From June 24 to June 30, 2020, around 52.1 percent of Hispanic adults aged 18 years and older in the U.S. reported having one or more adverse mental or behavioral health symptoms during the COVID-19 pandemic. This statistic illustrates the percentage of U.S. adults who reported adverse mental health symptoms, increased substance use, and suicidal ideation during COVID-19 pandemic from June 24 to 30, 2020, by race.

Note: SIAS  =  Social Interaction Anxiety Scale; SPS  =  Social Phobia Scale; Alcohol Use Freq.  =  number of days alcohol was consumed in the past 30 days; Episode Quantity  =  average number of standard drinks per drinking episode; Quantity  =  total number of standard drinks during the 30-day period; ARCs  =  alcohol-related consequences.Descriptive statistics.

Abstract (en): This study centered on two questions fundamental to understanding public opinion about the courts: (1) Do African Americans, Latinos, and Whites view the state courts differently? and (2) What impact did recent direct court experience have on people's opinions about state courts? Between March 22, 2000, and May 3, 2000, interviewers conducted 1,567 telephone interviews with randomly selected United States residents. Variables include respondents' gender, race, age, education, and other demographic information, respondents' perception of the fairness of local courts, including whether African Americans and Latinos were discriminated against, whether the respondent or a member of the respondent's household had been involved with the courts in the past 12 months, and if so, how fairly that case was conducted. This study centered on two questions fundamental to understanding public opinion about the courts: (1) Do African Americans, Latinos, and Whites view the state courts differently? and (2) What impact did recent direct court experience have on people's opinions about state courts? The distinctive contribution of this study was its exploration at a national level of the intersection of race and court experience with regard to perceptions of courts. Previous studies examined this intersection only in cities and states. This study also sought to answer several related questions: (1) Do Latinos have distinct views on state courts, or are their views closely tied to the views of Whites or African Americans? (2) Do individuals with recent court experience differ from those with more distant experience in the antecedents and nature of their views? (3) Does the type of experience (as jurors, litigants, or witnesses) affect racial groups differently, and does the presumed positive influence of jury service extend to African Americans and Latinos? (4) What level of support is there for courts playing nontraditional roles in cases involving complex emotional and social problems, like substance abuse and mental illness, and what does this level of support say about views of the courts as they currently stand? (5) How much does the media influence views of the courts relative to the influence of direct experience with courts? (6) What factors make people willing to return to courts in the future, and do these factors work in a similar way across racial and ethnic groups? Between March 22, 2000, and May 3, 2000, interviewers conducted 1,567 telephone interviews with randomly selected United States residents. The project staff at the National Center for State Courts designed the survey instrument and revised it based on a review by the advisory committee members and staff from the Indiana University Public Opinion Laboratory (IUPOL). Pretests were used to refine the survey instrument. The final instrument contained two sets of questions. The first set of questions was directed at all respondents. The second set of questions was directed only at those respondents with court experience in the last 12 months. A translator under contract to the IUPOL prepared a Spanish version of the survey instrument. The translation was reviewed and revised by two certified Spanish court interpreters. The interviews were conducted by professional interviewers at the IUPOL from special facilities on the Indiana University-Purdue University Indianapolis campus. All interviewers received at least four hours of general training in addition to specific training for this project. Most of the interviewers had previous experience in other survey research projects. Selected phone numbers were called until an interview was successfully conducted or: (1) the respondent refused to participate on three separate occasions, (2) a disconnected or not-in-service number was encountered, or (3) attempts to call the number yielded a no answer, busy signal, or answering machine on 20 separate occasions. Demographic variables include respondent gender, age, race, education, country of birth, part of Latin America to which ancestry was traced, age when moved to the continental United States, language most spoken in the household, marital status, number of people in the household, combined household income the year before, and state of residence. Other variables include respondents' assessments of how well local courts handle criminal, civil, family relations, and juvenile delinquency cases, respondents' ratings of local courts, police, and schools, rating o...

From June 24 to June 30, 2020, around 44.4 percent of adults living in the South in the U.S. reported having one or more adverse mental or behavioral health symptoms during the COVID-19 pandemic. This statistic illustrates the percentage of U.S. adults who reported adverse mental health symptoms, increased substance use, and suicidal ideation during COVID-19 pandemic from June 24 to 30, 2020, by region.

According to Cognitive Market Research, the global Opioid Use Disorder market size will be USD 2965.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 11.00% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1186.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 889.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.5% from 2024 to 2031.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 682.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 148.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 59.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.7% from 2024 to 2031.
The buprenorphine category held the highest Opioid Use Disorder market revenue share in 2024.

Market Dynamics of Opioid Use Disorder Market

Key Drivers for Opioid Use Disorder Market

Increased Opioid Addiction Rates to Increase the Demand Globally

The increasing prevalence of opioid addiction is mostly driving Opioid Use Disorder (OUD) market growth. Globally, addiction rates have increased as a result of the widespread usage of prescription opioids as well as illegal substances like heroin and synthetic opioids like fentanyl. The number of addiction cases has increased, and this has led to a critical need for medication-assisted treatment (MAT), behavioral treatments, and counseling as effective treatment options. Healthcare professionals, governments, and organizations are stepping up their efforts to tackle the opioid crisis as it worsens, which is driving up demand for OUD therapies. The market is rising as a result of the increased understanding of OUD as a chronic illness requiring all-encompassing care.

Growing Focus on Increasing Awareness in Government and Non-Governmental Organizations to Propel Market Growth

The growing popularity of both governmental and non-governmental groups in raising awareness about the dangers of opioid overdose is another significant driver propelling the market's growth. The number of individuals who have an opioid addiction has skyrocketed, leading many organizations to adopt a more comprehensive strategy to combat the issue. A lot of countries have increased their efforts to assist patients and reduce the consequences of opioid addiction. For instance, in March 2022, Health and Human Services (HHS) announced funding for programs that address and prevent substance use. This action was taken to reduce the misuse of prescription medications and increase access to medication-assisted therapy for opioid use disorder. More persons with opioid-related problems are expected to seek treatment if such measures are implemented. These factors are expected to impact the worldwide market positively throughout the forecast time.

Restraint Factor for the Opioid Use Disorder Market

Social Obstacles and Stigma to Limit the Sales

The market for opioid use disorders (OUDs) is significantly hampered by stigma and social constraints. People who are afraid of being judged, discriminated against, or shunned by society are frequently deterred from getting treatment due to the pervasive stigma associated with opiate addiction. Inadequate support and financing for OUD treatment programs result from this stigma, which not only impacts those who are addicted but also has an impact on lawmakers, healthcare professionals, and the general public. Social hurdles that impede open discussions about addiction and treatment choices, such as cultural views and lack of awareness, exacerbate the issue. Many people so go untreated, which hinders attempts to address the opioid crisis and slows the market's growth for OUD treatment.

Impact of Covid-19 on the Opioid Use Disorder Market

The market for opioid use disorders (OUDs) has been significantly impacted by the COVID-19 pandemic. Because of the increased stress, uncertainty about the...